Latest Event Suggests that Progenics’ Drug Is Working
Research - Progenics Pharmaceuticals (PGNX)Â listed a new trial on clinicaltrials.gov on Monday that supports the PGNX long thesis. The stock has a had a nice run this … Continue Reading
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Endocyte Files to Sell Stock
Insights - Endocyte (ECYT) on Monday filed to sell $60 million in common stock through an At The Market sales agreement with Cowen and Company. PropThink discussed ECYT at length here and here. … Continue Reading
PremiumRecapping Our Top Stories – and Trades – in Biotech from the Week
Insights - AcelRx (ACRX) announced on Monday a partnership with Grunenthal GmbH for the commercialization of Zalviso, the company’s patient-controlled analgesia product, in Europe and Australia. On Thursday, AcelRx entered into … Continue Reading
Read now
Vertex CF Drug Misses Endpoint but Not All is Lost
Insights - Vertex Pharmaceuticals (VRTX) announced that Kalydeco, its drug for cystic fibrosis (CF), showed potential benefit in patients 18 or older, despite missing a phase 3 … Continue Reading
Read now
Retrophin Introduces New Candidate, Plans NASDAQ Listing
Insights - On the heels of dropping its bid to acquire troubled Transcept Pharmaceuticals (TSPT), Retrophin, Inc. (RTRX) announced its newest clinical development candidate on Wednesday: RE-034 … Continue Reading
Read now
Alcobra’s Mid-Stage Study Supports the Long Thesis
Insights - Alcobra Ltd. (ADHD) announced on Monday that its proprietary non-stimulant drug candidate, Metadoxine ER (MG01CI), delivered statistically positive results in a phase 2b clinical trial in adults with … Continue Reading
Read now
Amgen’s PCSK9 Inhibitor Confirms Efficacy in Another Phase 3
Insights - Amgen’s PCSK9 inhibitor, evolucumab (AMG145) met its co-primary endpoints in a phase 3 trial: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week … Continue Reading
Read now